Drug Targets for HIV
The human immunodeficiency virus remains prevalent in the population, yet it as silently moved out of the public’s consciousness, overshadowed by COVID19 and drug cocktails that can control its progression. Over the last three decades great progress has
Talking Biotech with Dr. Kevin Folta · Kevin M. Folta
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The human immunodeficiency virus remains prevalent in the population, yet it as silently moved out of the public’s consciousness, overshadowed by COVID19 and drug cocktails that can control its progression. Over the last three decades great progress has been made in understanding the virus and how it interacts with cells. This, plus the identification of genetic determinants of resistance to HIV have presented researchers with new drug targets. These may represent future therapies and perhaps cures. Today’s guest is Dr. Luca Vangelista from Nazarbayev University in Kazakhstan. His research examines a protein receptor called CCR5 that is a critical player in the HIV infection cycle.
Dr. Vangelista’s recent review may be accessed here.
Here is Dr. Vangelista’s website.
# COLABRA
Talking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/
# TALKING BIOTECH
Twitter: https://twitter.com/talkingbiotech
Website: https://www.colabra.app/podcasts/talking-biotech/
Instagram: https://www.instagram.com/colabrahq
The Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.